LEXICON'S SOTAGLIFLOZIN WINS FDA NOD FOR HEART FAILURE; UP 11% AFTER HOURS
- The US FDA has approved Lexicon Pharmaceuticals' Inpefa (sotagliflozin) to cut the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits.
- The oral pill is intended for those with heart failure, type 2 diabetes, chronic kidney disease, or other CV disease risk factors.
- Lexicon (NASDAQ:LXRX) shares are up ~11% in after-hours trading Friday.
- The company expects Inpefa to be available by the end of June.
- The approval was supported by two double-blind, placebo-controlled trials. One of them showed that Inpefa reduced the risk of the composite of hospitalizations for heart failure, urgent visits for heart failure, and CV death by 33% compared to placebo.
More on Lexicon Pharmaceuticals
Now read: Mirati tumbles after study failure for cancer drug; Oppenheimer upgrades